No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, 3wylA, 1.0000, 0.00, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 5- METHOXY-3-(1-PHENYL-1H-PYRAZOL-5-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL) PYRIDAZIN-4(1H)-ONE
2, 5axqA, 0.9976, 0.31, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH HIGHLY POTENT AND BRAIN-PENETRANT PDE10A INHIBITOR WITH 2-OXINDOLE SCAFFOLD
3, 5axpA, 0.9975, 0.32, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 1- (2-FLUORO-4-(2-OXO-13-OXAZOLIDIN-3-YL)PHENYL)-5-METHOXY-3-(1-PHENYL- 1H-PYRAZOL-5-YL)PYRIDAZIN-4(1H)-ONE
4, 5b4kA, 0.9971, 0.35, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PDE10A COMPLEXED WITH N-(4-((5-METHYL-5H-PYRROLO[32-D]PYRIMIDIN-4-YL)OXY)PHENYL)-1H- BENZIMIDAZOL-2-AMINE
5, 3wykA, 0.9971, 0.35, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 3- (1-PHENYL-1H-PYRAZOL-5-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)PYRIDAZIN- 4(1H)-ONE
6, 5b4lA, 0.9967, 0.37, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PDE10A COMPLEXED WITH 1-(CYCLOPROPYLMETHYL)-5-(2-(23-DIHYDRO-1H-IMIDAZO[12- A]BENZIMIDAZOL-1-YL)ETHOXY)-3-(1-PHENYL-1H-PYRAZOL-5-YL)PYRIDAZIN- 4(1H)-ONE
7, 5dh5B, 0.9964, 0.39, 1.000, 323, 315, PDE10 COMPLEXED WITH N-[(1-METHYLPYRAZOL-4-YL)METHYL]-5-[[(1S2S)-2- (2-PYRIDYL)CYCLOPROPYL]METHOXY]PYRAZOLO[15-A]PYRIMIDIN-7-AMINE
8, 3wymA, 0.9964, 0.39, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 1- (2-FLUORO-4-(1H-PYRAZOL-1-YL)PHENYL)-5-METHOXY-3-(1-PHENYL-1H- PYRAZOL-5-YL)PYRIDAZIN-4(1H)-ONE
9, 3ui7B, 0.9961, 0.41, 1.000, 315, 315, DISCOVERY OF ORALLY ACTIVE PYRAZOLOQUINOLINE AS A POTENT PDE10 INHIBITOR FOR THE MANAGEMENT OF SCHIZOPHRENIA
10, 4yqhB, 0.9959, 0.42, 1.000, 321, 315, 2-[2-(4-PHENYL-1H-IMIDAZOL-2-YL)ETHYL]QUINOXALINE (SUNOVION COMPOUND 14) CO-CRYSTALLIZED WITH PDE10A
11, 4ajgD, 0.9959, 0.41, 1.000, 322, 315, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
12, 4ys7B, 0.9957, 0.43, 1.000, 317, 315, CO-CRYSTAL STRUCTURE OF 2-[2-(58-DIMETHYL[124]TRIAZOLO[15- A]PYRAZIN-2-YL)ETHYL]-3-METHYL-3H-IMIDAZO[45-F]QUINOLINE (COMPOUND 39) WITH PDE10A
13, 5c2aA, 0.9954, 0.44, 1.000, 323, 315, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-N-[(24-DIMETHYLTHIAZOL-5- YL)METHYL]-5-METHYL-PYRIMIDIN-4-AMINE
14, 4zo5B, 0.9954, 0.44, 1.000, 323, 315, PDE10 COMPLEXED WITH 4-ISOPROPOXY-2-(2-(3-(4-METHOXYPHENYL)-4-OXO-34- DIHYDROQUINAZOLIN-2-YL)ETHYL)ISOINDOLINE-13-DIONE
15, 3uuoB, 0.9954, 0.44, 1.000, 315, 315, THE DISCOVERY OF POTENT SELECTIVITY AND ORALLY BIOAVAILABLE PYROZOLOQUINOLINES AS PDE10 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA
16, 4aelB, 0.9953, 0.45, 1.000, 323, 315, PDE10A IN COMPLEX WITH THE INHIBITOR AZ5
17, 5xuiA, 0.9952, 0.45, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 2-METHYL-5-[2-([12 4]TRIAZOLO[15-A]PYRIMIDIN-2-YL)ET HYL]PYRAZOLO[15-A]PYRIMIDIN-7-OL
18, 4ajdD, 0.9952, 0.45, 1.000, 323, 315, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
19, 4zo5A, 0.9951, 0.46, 1.000, 323, 315, PDE10 COMPLEXED WITH 4-ISOPROPOXY-2-(2-(3-(4-METHOXYPHENYL)-4-OXO-34- DIHYDROQUINAZOLIN-2-YL)ETHYL)ISOINDOLINE-13-DIONE
20, 5c2eB, 0.9950, 0.46, 1.000, 323, 315, PDE10 COMPLEXED WITH6-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL)METHYL]-5- METHYL-2-[2-(2-PYRIDYL)ETHOXY]PYRIMIDIN-4-AMINE
21, 5c2aB, 0.9950, 0.46, 1.000, 323, 315, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-N-[(24-DIMETHYLTHIAZOL-5- YL)METHYL]-5-METHYL-PYRIMIDIN-4-AMINE
22, 5c2eA, 0.9947, 0.48, 1.000, 323, 315, PDE10 COMPLEXED WITH6-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL)METHYL]-5- METHYL-2-[2-(2-PYRIDYL)ETHOXY]PYRIMIDIN-4-AMINE
23, 5axpB, 0.9947, 0.47, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 1- (2-FLUORO-4-(2-OXO-13-OXAZOLIDIN-3-YL)PHENYL)-5-METHOXY-3-(1-PHENYL- 1H-PYRAZOL-5-YL)PYRIDAZIN-4(1H)-ONE
24, 4wn1A, 0.9947, 0.48, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 1-METHYL-5-(1-METHYL-3- {[4-(QUINOLIN-2-YL)PHENOXY]METHYL}-1H-PYRAZOL-4-YL)PYRIDIN-2(1H)-ONE
25, 5dh4B, 0.9946, 0.48, 1.000, 322, 315, PDE10 COMPLEXED WITH 5-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL) METHYL]PYRAZOLO[15-A]PYRIMIDIN-7-AMINE
26, 3ws9A, 0.9946, 0.48, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH A BENZIMDAZOLE INHIBITOR
27, 4yqhA, 0.9943, 0.49, 1.000, 321, 315, 2-[2-(4-PHENYL-1H-IMIDAZOL-2-YL)ETHYL]QUINOXALINE (SUNOVION COMPOUND 14) CO-CRYSTALLIZED WITH PDE10A
28, 4ajdA, 0.9943, 0.49, 1.000, 324, 315, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
29, 5axqB, 0.9942, 0.50, 1.000, 316, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH HIGHLY POTENT AND BRAIN-PENETRANT PDE10A INHIBITOR WITH 2-OXINDOLE SCAFFOLD
30, 5b4lB, 0.9941, 0.50, 1.000, 316, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PDE10A COMPLEXED WITH 1-(CYCLOPROPYLMETHYL)-5-(2-(23-DIHYDRO-1H-IMIDAZO[12- A]BENZIMIDAZOL-1-YL)ETHOXY)-3-(1-PHENYL-1H-PYRAZOL-5-YL)PYRIDAZIN- 4(1H)-ONE
31, 5xuiB, 0.9940, 0.50, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 2-METHYL-5-[2-([12 4]TRIAZOLO[15-A]PYRIMIDIN-2-YL)ET HYL]PYRAZOLO[15-A]PYRIMIDIN-7-OL
32, 3wykB, 0.9940, 0.51, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 3- (1-PHENYL-1H-PYRAZOL-5-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)PYRIDAZIN- 4(1H)-ONE
33, 5b4kB, 0.9939, 0.51, 1.000, 316, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PDE10A COMPLEXED WITH N-(4-((5-METHYL-5H-PYRROLO[32-D]PYRIMIDIN-4-YL)OXY)PHENYL)-1H- BENZIMIDAZOL-2-AMINE
34, 3wi2B, 0.9939, 0.51, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH INHIBITOR
35, 4ys7A, 0.9938, 0.52, 1.000, 322, 315, CO-CRYSTAL STRUCTURE OF 2-[2-(58-DIMETHYL[124]TRIAZOLO[15- A]PYRAZIN-2-YL)ETHYL]-3-METHYL-3H-IMIDAZO[45-F]QUINOLINE (COMPOUND 39) WITH PDE10A
36, 3wymB, 0.9938, 0.52, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 1- (2-FLUORO-4-(1H-PYRAZOL-1-YL)PHENYL)-5-METHOXY-3-(1-PHENYL-1H- PYRAZOL-5-YL)PYRIDAZIN-4(1H)-ONE
37, 3ws8A, 0.9938, 0.52, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
38, 2y0jB, 0.9936, 0.37, 1.000, 314, 314, TRIAZOLOQUINAZOLINES AS A NOVEL CLASS OF PHOSPHODIESTERASE 10A (PDE10A) INHIBITORS PART 2 LEAD-OPTIMISATION.
39, 4mscA, 0.9935, 0.53, 1.000, 328, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT1595 (2-[(QUINOLIN-7- YLOXY)METHYL]QUINOLINE)
40, 5uwfD, 0.9934, 0.53, 1.000, 324, 315, CRYSTAL STRUCTURE OF HUMAN PDE10A IN COMPLEX WITH INHIBITOR 16D
41, 5c1wA, 0.9934, 0.53, 1.000, 325, 315, PDE10 COMPLEXED WITH 46-DICHLORO-2-CYCLOPROPYL-5-METHYL-PYRIMIDINE
42, 4wn1B, 0.9933, 0.53, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 1-METHYL-5-(1-METHYL-3- {[4-(QUINOLIN-2-YL)PHENOXY]METHYL}-1H-PYRAZOL-4-YL)PYRIDIN-2(1H)-ONE
43, 4msnA, 0.9933, 0.53, 1.000, 330, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0451 (8-NITROQUINOLINE)
44, 3ws8B, 0.9933, 0.53, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
45, 4mshA, 0.9932, 0.54, 1.000, 328, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0143 ((2S)-4-CHLORO-23- DIHYDRO-13-BENZOTHIAZOL-2-AMINE)
46, 2ouyA, 0.9932, 0.54, 0.997, 330, 315, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D564A IN COMPLEX WITH CAMP.
47, 5xujB, 0.9931, 0.55, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 7-(4-CHLOROPHENYL)-2- METHYLPYRAZOLO[15-A]PYRIMIDINE
48, 4lm2A, 0.9931, 0.55, 1.000, 330, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT462
49, 4llpA, 0.9931, 0.55, 1.000, 330, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT401
50, 3ws9B, 0.9931, 0.54, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH A BENZIMDAZOLE INHIBITOR
51, 3wi2A, 0.9931, 0.54, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH INHIBITOR
52, 4lm1A, 0.9930, 0.55, 1.000, 332, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT450
53, 3sn7A, 0.9930, 0.55, 1.000, 322, 315, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
54, 2weyA, 0.9930, 0.55, 1.000, 324, 315, HUMAN PDE-PAPAVERINE COMPLEX OBTAINED BY LIGAND SOAKING OF CROSS-LINKED PROTEIN CRYSTALS
55, 2ouqA, 0.9930, 0.55, 1.000, 326, 315, CRYSTAL STRUCTURE OF PDE10A2 IN COMPLEX WITH GMP
56, 4fcbA, 0.9929, 0.55, 1.000, 322, 315, POTENT AND SELECTIVE PHOSPHODIESTERASE 10A INHIBITORS
57, 4llxA, 0.9928, 0.56, 1.000, 330, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT434
58, 2oupA, 0.9928, 0.56, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A
59, 5c28A, 0.9927, 0.56, 1.000, 325, 315, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-5-METHYL-PYRIMIDIN-4-AMINE
60, 3sniA, 0.9927, 0.56, 1.000, 322, 315, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
61, 2ouvA, 0.9927, 0.56, 0.997, 325, 315, CRYSTAL STRUCTURE OF PDE10A2 MUTANT OF D564N
62, 4ms0A, 0.9926, 0.57, 1.000, 330, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0443 (6-CHLOROPYRIMIDINE- 24-DIAMINE)
63, 4mrwA, 0.9926, 0.56, 1.000, 330, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0120 (7-CHLOROQUINOLIN-4- OL)
64, 4llkA, 0.9926, 0.57, 1.000, 330, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT217
65, 4lljA, 0.9926, 0.57, 1.000, 329, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT214
66, 4ajmD, 0.9926, 0.42, 1.000, 320, 314, DEVELOPMENT OF A PLATE-BASED OPTICAL BIOSENSOR METHODOLOGY TO IDENTIFY PDE10 FRAGMENT INHIBITORS
67, 4mseA, 0.9925, 0.57, 1.000, 330, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT1597 (2-({[(2S)-2-METHYL- 23-DIHYDRO-13-BENZOTHIAZOL-5-YL]OXY}METHYL)QUINOLINE)
68, 4lkqA, 0.9925, 0.57, 1.000, 330, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT017
69, 4fcdA, 0.9925, 0.57, 1.000, 322, 315, POTENT AND SELECTIVE PHOSPHODIESTERASE 10A INHIBITORS
70, 2ourA, 0.9925, 0.57, 0.997, 324, 315, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A IN COMPLEX WITH CAMP
71, 4mrzA, 0.9924, 0.57, 1.000, 330, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0429 (4-METHYL-3- NITROPYRIDIN-2-AMINE)
72, 4lm4A, 0.9924, 0.57, 1.000, 330, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT902
73, 4lm3A, 0.9924, 0.57, 1.000, 331, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT464
74, 3snlA, 0.9924, 0.57, 1.000, 322, 315, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
75, 2weyB, 0.9924, 0.57, 1.000, 324, 315, HUMAN PDE-PAPAVERINE COMPLEX OBTAINED BY LIGAND SOAKING OF CROSS-LINKED PROTEIN CRYSTALS
76, 4lm0A, 0.9923, 0.58, 1.000, 330, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT448
77, 4msaA, 0.9922, 0.58, 1.000, 330, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0449 (5-NITRO-1H- BENZIMIDAZOLE)
78, 2ounA, 0.9922, 0.58, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A2 IN COMPLEX WITH AMP
79, 2ouuA, 0.9921, 0.59, 0.997, 329, 315, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A IN COMPLEX WITH CGMP
80, 2ousA, 0.9920, 0.59, 0.997, 326, 315, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A
81, 5c2hB, 0.9918, 0.47, 1.000, 322, 314, PDE10 COMPLEXED WITH 6-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL)METHYL]-5- METHYL-2-[3-(2-QUINOLYL)PROPOXY]PYRIMIDIN-4-AMINE
82, 2y0jA, 0.9915, 0.48, 1.000, 314, 314, TRIAZOLOQUINAZOLINES AS A NOVEL CLASS OF PHOSPHODIESTERASE 10A (PDE10A) INHIBITORS PART 2 LEAD-OPTIMISATION.
83, 4ajgA, 0.9912, 0.49, 1.000, 321, 314, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
84, 3ui7A, 0.9899, 0.55, 1.000, 315, 314, DISCOVERY OF ORALLY ACTIVE PYRAZOLOQUINOLINE AS A POTENT PDE10 INHIBITOR FOR THE MANAGEMENT OF SCHIZOPHRENIA
85, 5uwfC, 0.9896, 0.56, 1.000, 323, 314, CRYSTAL STRUCTURE OF HUMAN PDE10A IN COMPLEX WITH INHIBITOR 16D
86, 4ajfA, 0.9896, 0.56, 1.000, 327, 314, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
87, 3wylB, 0.9886, 0.47, 1.000, 313, 313, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 5- METHOXY-3-(1-PHENYL-1H-PYRAZOL-5-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL) PYRIDAZIN-4(1H)-ONE
88, 4aelA, 0.9878, 0.50, 1.000, 320, 313, PDE10A IN COMPLEX WITH THE INHIBITOR AZ5
89, 4xy2B, 0.9872, 0.53, 1.000, 322, 313, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH ASP9436
90, 5dh5A, 0.9862, 0.43, 1.000, 321, 312, PDE10 COMPLEXED WITH N-[(1-METHYLPYRAZOL-4-YL)METHYL]-5-[[(1S2S)-2- (2-PYRIDYL)CYCLOPROPYL]METHOXY]PYRAZOLO[15-A]PYRIMIDIN-7-AMINE
91, 4bbxB, 0.9860, 0.44, 1.000, 312, 312, DISCOVERY OF A POTENT SELECTIVE AND ORALLY ACTIVE PDE10A INHIBITOR FOR THE TREATMENT OF SCHIZOPHRENIA
92, 4ajmA, 0.9857, 0.45, 1.000, 320, 312, DEVELOPMENT OF A PLATE-BASED OPTICAL BIOSENSOR METHODOLOGY TO IDENTIFY PDE10 FRAGMENT INHIBITORS
93, 5k9rA, 0.9856, 0.46, 0.997, 312, 312, PDE10A WITH IMIDAZOPYRAZINE INHIBITOR
94, 5k9rB, 0.9843, 0.52, 0.997, 312, 312, PDE10A WITH IMIDAZOPYRAZINE INHIBITOR
95, 4bbxA, 0.9843, 0.52, 1.000, 312, 312, DISCOVERY OF A POTENT SELECTIVE AND ORALLY ACTIVE PDE10A INHIBITOR FOR THE TREATMENT OF SCHIZOPHRENIA
96, 4mscB, 0.9738, 1.22, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT1595 (2-[(QUINOLIN-7- YLOXY)METHYL]QUINOLINE)
97, 4ajfD, 0.9738, 1.21, 1.000, 324, 315, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
98, 4mshB, 0.9734, 1.23, 1.000, 325, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0143 ((2S)-4-CHLORO-23- DIHYDRO-13-BENZOTHIAZOL-2-AMINE)
99, 4mseB, 0.9731, 1.22, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT1597 (2-({[(2S)-2-METHYL- 23-DIHYDRO-13-BENZOTHIAZOL-5-YL]OXY}METHYL)QUINOLINE)
100, 5c2hA, 0.9728, 0.46, 1.000, 308, 308, PDE10 COMPLEXED WITH 6-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL)METHYL]-5- METHYL-2-[3-(2-QUINOLYL)PROPOXY]PYRIMIDIN-4-AMINE
101, 4msnB, 0.9728, 1.24, 1.000, 325, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0451 (8-NITROQUINOLINE)
102, 4mrwB, 0.9713, 1.30, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0120 (7-CHLOROQUINOLIN-4- OL)
103, 4ms0B, 0.9712, 1.30, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0443 (6-CHLOROPYRIMIDINE- 24-DIAMINE)
104, 4msaB, 0.9711, 1.29, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0449 (5-NITRO-1H- BENZIMIDAZOLE)
105, 4lm2B, 0.9711, 1.30, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT462
106, 4mrzB, 0.9709, 1.29, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0429 (4-METHYL-3- NITROPYRIDIN-2-AMINE)
107, 4llxB, 0.9709, 1.30, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT434
108, 4lkqB, 0.9709, 1.30, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT017
109, 4lm3B, 0.9708, 1.30, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT464
110, 4llkB, 0.9708, 1.31, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT217
111, 4lm4B, 0.9707, 1.30, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT902
112, 4lm1B, 0.9707, 1.31, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT450
113, 4lm0B, 0.9707, 1.30, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT448
114, 2oupB, 0.9707, 1.30, 1.000, 325, 315, CRYSTAL STRUCTURE OF PDE10A
115, 2ouvB, 0.9706, 1.30, 0.997, 328, 315, CRYSTAL STRUCTURE OF PDE10A2 MUTANT OF D564N
116, 5dh4A, 0.9698, 0.46, 1.000, 307, 307, PDE10 COMPLEXED WITH 5-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL) METHYL]PYRAZOLO[15-A]PYRIMIDIN-7-AMINE
117, 2ousB, 0.9696, 1.32, 0.997, 329, 315, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A
118, 2ounB, 0.9694, 1.33, 1.000, 328, 315, CRYSTAL STRUCTURE OF PDE10A2 IN COMPLEX WITH AMP
119, 4dffA, 0.9688, 0.51, 1.000, 307, 307, THE SAR DEVELOPMENT OF DIHYDROIMIDAZOISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA
120, 4mvhB, 0.9668, 0.72, 1.000, 308, 308, CRYSTAL STRUCTURE OF PDE10A WITH NOVEL KETO-BENZIMIDAZOLE INHIBITOR
121, 4p1rB, 0.9663, 0.74, 1.000, 308, 308, CRYSTAL STRUCTURE OF PDE10A WITH IMIDAZO[45-B]PYRIDINES AS POTENT AND SELECTIVE INHIBITORS
122, 4heuB, 0.9662, 0.74, 1.000, 308, 308, CRYSTAL STRUCTURE OF PDE10A WITH A BIARYL ETHER INHIBITOR ((1-(3-(4- ((1H-BENZO[D]IMIDAZOL-2-YL)AMINO)PHENOXY)PYRIDIN-2-YL)PIPERIDIN-4- YL)METHANOL)
123, 4hf4B, 0.9659, 0.75, 1.000, 308, 308, CRYSTAL STRUCTURE OF PDE10A WITH A BIARYL ETHER INHIBITOR (1-(1-(3-(4- (BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYRAZIN-2-YL)PIPERIDIN-4-YL) ETHANOL)
124, 4hf4A, 0.9656, 1.20, 1.000, 318, 310, CRYSTAL STRUCTURE OF PDE10A WITH A BIARYL ETHER INHIBITOR (1-(1-(3-(4- (BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYRAZIN-2-YL)PIPERIDIN-4-YL) ETHANOL)
125, 4heuA, 0.9656, 1.19, 1.000, 318, 310, CRYSTAL STRUCTURE OF PDE10A WITH A BIARYL ETHER INHIBITOR ((1-(3-(4- ((1H-BENZO[D]IMIDAZOL-2-YL)AMINO)PHENOXY)PYRIDIN-2-YL)PIPERIDIN-4- YL)METHANOL)
126, 4p0nB, 0.9655, 0.76, 1.000, 308, 308, CRYSTAL STRUCTURE OF PDE10A WITH A NOVEL IMIDAZO[45-B]PYRIDINE INHIBITOR
127, 4muwA, 0.9654, 1.21, 1.000, 318, 310, CRYSTAL STRUCTURE OF PDE10A WITH NOVEL KETO-BENZIMIDAZOLE INHIBITOR
128, 5c29A, 0.9653, 0.52, 1.000, 307, 306, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-5-METHYL-N-PROPYL- PYRIMIDIN-4-AMINE
129, 4ddlB, 0.9653, 0.77, 1.000, 308, 308, PDE10A CRYSTAL STRUCTURE COMPLEXED WITH NOVEL INHIBITOR
130, 4p1rA, 0.9651, 1.20, 1.000, 318, 310, CRYSTAL STRUCTURE OF PDE10A WITH IMIDAZO[45-B]PYRIDINES AS POTENT AND SELECTIVE INHIBITORS
131, 4ddlA, 0.9649, 1.21, 1.000, 318, 310, PDE10A CRYSTAL STRUCTURE COMPLEXED WITH NOVEL INHIBITOR
132, 5edgA, 0.9633, 1.07, 0.997, 312, 309, HUMAN PDE10A IN COMPLEX WITH 3-(2-CHLORO-5-PHENYL-3H-IMIDAZOL-4-YL)-1- (3-TRIFLUOROMETHOXY-PHENYL)-1H-PYRIDAZIN-4-ONE AT 2.30A
133, 5edeA, 0.9630, 1.10, 0.997, 313, 309, HUMAN PDE10A IN COMPLEX WITH 1-(4-CHLORO-PHENYL)-3-METHYL-1H-THIENO[2 3-C]PYRAZOLE-5-CARBOXYLIC ACID (TETRAHYDRO-FURAN-2-YLMETHYL)-AMIDE AT 2.2A
134, 4tpmB, 0.9629, 0.75, 1.000, 307, 307, CRYSTAL STRUCTURE OF 2-(3-ALKOXY-1-AZETIDINYL) QUINOLINES AS PDE10A INHIBITORS
135, 4lljB, 0.9629, 1.26, 1.000, 322, 312, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT214
136, 4tppB, 0.9627, 0.75, 1.000, 307, 307, 2-(3-ALKOXY-1-AZETIDINYL) QUINOLINES AS NOVEL PDE10A INHIBITORS
137, 5edgB, 0.9626, 1.11, 0.997, 314, 309, HUMAN PDE10A IN COMPLEX WITH 3-(2-CHLORO-5-PHENYL-3H-IMIDAZOL-4-YL)-1- (3-TRIFLUOROMETHOXY-PHENYL)-1H-PYRIDAZIN-4-ONE AT 2.30A
138, 4mvhA, 0.9625, 0.77, 1.000, 307, 307, CRYSTAL STRUCTURE OF PDE10A WITH NOVEL KETO-BENZIMIDAZOLE INHIBITOR
139, 5edhA, 0.9623, 1.11, 1.000, 311, 309, HUMAN PDE10A 8-ETHYL-5-METHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL-124- TRIAZOL-3-YL)ETHYL]-[124]TRIAZOLO[15-C]PYRIMIDINE 2.03A H3 RFREE=22.7%
140, 5edgC, 0.9623, 1.08, 0.997, 312, 309, HUMAN PDE10A IN COMPLEX WITH 3-(2-CHLORO-5-PHENYL-3H-IMIDAZOL-4-YL)-1- (3-TRIFLUOROMETHOXY-PHENYL)-1H-PYRIDAZIN-4-ONE AT 2.30A
141, 5edeC, 0.9622, 1.09, 0.997, 312, 309, HUMAN PDE10A IN COMPLEX WITH 1-(4-CHLORO-PHENYL)-3-METHYL-1H-THIENO[2 3-C]PYRAZOLE-5-CARBOXYLIC ACID (TETRAHYDRO-FURAN-2-YLMETHYL)-AMIDE AT 2.2A
142, 5i2rA, 0.9621, 1.12, 1.000, 312, 309, HUMAN PDE10A IN COMPLEX WITH 3-(2-PHENYLPYRAZOL-3-YL)-1-[3- (TRIFLUOROMETHOXY)PHENYL]PYRIDAZIN-4-ONE
143, 5ediA, 0.9621, 1.12, 0.997, 312, 309, HUMAN PDE10A 6-CHLORO-58-DIMETHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL- 2H-[124]TRIAZOL-3-YL)-ETHYL]-[124]TRIAZOLO[15-A]PYRIDINE 2.20A H3 RFREE=23.5%
144, 4p0nA, 0.9621, 0.78, 1.000, 307, 307, CRYSTAL STRUCTURE OF PDE10A WITH A NOVEL IMIDAZO[45-B]PYRIDINE INHIBITOR
145, 5ediC, 0.9619, 1.10, 0.997, 312, 309, HUMAN PDE10A 6-CHLORO-58-DIMETHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL- 2H-[124]TRIAZOL-3-YL)-ETHYL]-[124]TRIAZOLO[15-A]PYRIDINE 2.20A H3 RFREE=23.5%
146, 5edhC, 0.9619, 1.10, 1.000, 312, 309, HUMAN PDE10A 8-ETHYL-5-METHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL-124- TRIAZOL-3-YL)ETHYL]-[124]TRIAZOLO[15-C]PYRIMIDINE 2.03A H3 RFREE=22.7%
147, 3uuoA, 0.9619, 0.53, 1.000, 305, 305, THE DISCOVERY OF POTENT SELECTIVITY AND ORALLY BIOAVAILABLE PYROZOLOQUINOLINES AS PDE10 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA
148, 3lxgA, 0.9618, 0.78, 0.964, 308, 307, CRYSTAL STRUCTURE OF RAT PHOSPHODIESTERASE 10A IN COMPLEX WITH LIGAND WEB-3
149, 5ediB, 0.9617, 1.13, 0.997, 319, 309, HUMAN PDE10A 6-CHLORO-58-DIMETHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL- 2H-[124]TRIAZOL-3-YL)-ETHYL]-[124]TRIAZOLO[15-A]PYRIDINE 2.20A H3 RFREE=23.5%
150, 5i2rB, 0.9615, 1.16, 1.000, 316, 309, HUMAN PDE10A IN COMPLEX WITH 3-(2-PHENYLPYRAZOL-3-YL)-1-[3- (TRIFLUOROMETHOXY)PHENYL]PYRIDAZIN-4-ONE
151, 5edeB, 0.9615, 1.14, 0.997, 314, 309, HUMAN PDE10A IN COMPLEX WITH 1-(4-CHLORO-PHENYL)-3-METHYL-1H-THIENO[2 3-C]PYRAZOLE-5-CARBOXYLIC ACID (TETRAHYDRO-FURAN-2-YLMETHYL)-AMIDE AT 2.2A
152, 5i2rC, 0.9614, 1.12, 1.000, 312, 309, HUMAN PDE10A IN COMPLEX WITH 3-(2-PHENYLPYRAZOL-3-YL)-1-[3- (TRIFLUOROMETHOXY)PHENYL]PYRIDAZIN-4-ONE
153, 5edhB, 0.9614, 1.14, 1.000, 314, 309, HUMAN PDE10A 8-ETHYL-5-METHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL-124- TRIAZOL-3-YL)ETHYL]-[124]TRIAZOLO[15-C]PYRIMIDINE 2.03A H3 RFREE=22.7%
154, 3jwqA, 0.9607, 1.43, 0.420, 324, 314, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH SILDENAFIL
155, 3jwqC, 0.9595, 1.45, 0.420, 327, 314, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH SILDENAFIL
156, 3jwqB, 0.9595, 1.45, 0.420, 324, 314, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH SILDENAFIL
157, 1t9sB, 0.9595, 1.39, 0.387, 326, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A IN COMPLEX WITH GMP
158, 4muwB, 0.9594, 0.76, 1.000, 306, 306, CRYSTAL STRUCTURE OF PDE10A WITH NOVEL KETO-BENZIMIDAZOLE INHIBITOR
159, 5edhD, 0.9592, 1.29, 0.994, 312, 309, HUMAN PDE10A 8-ETHYL-5-METHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL-124- TRIAZOL-3-YL)ETHYL]-[124]TRIAZOLO[15-C]PYRIMIDINE 2.03A H3 RFREE=22.7%
160, 5edgD, 0.9590, 1.09, 0.994, 312, 308, HUMAN PDE10A IN COMPLEX WITH 3-(2-CHLORO-5-PHENYL-3H-IMIDAZOL-4-YL)-1- (3-TRIFLUOROMETHOXY-PHENYL)-1H-PYRIDAZIN-4-ONE AT 2.30A
161, 5jo3B, 0.9588, 1.41, 0.387, 323, 313, PDE5A FOR NAV1.7
162, 3jwrB, 0.9588, 1.46, 0.420, 328, 314, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH 3-ISOBUTYL-1-METHYLXANTHINE (IBMX) AND PDE6 GAMMA-SUBUNIT INHIBITORY PEPTIDE 70-87.
163, 3jabO, 0.9588, 1.46, 0.420, 328, 314, DOMAIN ORGANIZATION AND CONFORMATIONAL PLASTICITY OF THE G PROTEIN EFFECTOR PDE6
164, 3jabC, 0.9588, 1.46, 0.420, 328, 314, DOMAIN ORGANIZATION AND CONFORMATIONAL PLASTICITY OF THE G PROTEIN EFFECTOR PDE6
165, 2chmA, 0.9588, 1.42, 0.387, 323, 313, CRYSTAL STRUCTURE OF N2 SUBSTITUTED PYRAZOLO PYRIMIDINONES- A FLIPPED BINDING MODE IN PDE5
166, 1tbfA, 0.9588, 1.41, 0.390, 326, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A IN COMPLEX WITH SILDENAFIL
167, 5edeD, 0.9587, 1.11, 0.994, 312, 308, HUMAN PDE10A IN COMPLEX WITH 1-(4-CHLORO-PHENYL)-3-METHYL-1H-THIENO[2 3-C]PYRAZOLE-5-CARBOXYLIC ACID (TETRAHYDRO-FURAN-2-YLMETHYL)-AMIDE AT 2.2A
168, 3jwrA, 0.9587, 1.47, 0.420, 323, 314, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH 3-ISOBUTYL-1-METHYLXANTHINE (IBMX) AND PDE6 GAMMA-SUBUNIT INHIBITORY PEPTIDE 70-87.
169, 1xozA, 0.9587, 1.42, 0.387, 326, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A IN COMPLEX WITH TADALAFIL
170, 3hdzA, 0.9586, 1.42, 0.387, 323, 313, IDENTIFICATION SYNTHESIS AND SAR OF AMINO SUBSTITUTED PYRIDO[3 2B]PRYAZIONES AS POTENT AND SELECTIVE PDE5 INHIBITORS
171, 5ediD, 0.9585, 1.11, 0.994, 316, 308, HUMAN PDE10A 6-CHLORO-58-DIMETHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL- 2H-[124]TRIAZOL-3-YL)-ETHYL]-[124]TRIAZOLO[15-A]PYRIDINE 2.20A H3 RFREE=23.5%
172, 2o8hA, 0.9585, 0.79, 0.967, 307, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF RAT PHOSPHODIESTERASE 10A
173, 3jwqD, 0.9584, 1.47, 0.424, 323, 314, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH SILDENAFIL
174, 5i2rD, 0.9578, 1.14, 0.997, 312, 308, HUMAN PDE10A IN COMPLEX WITH 3-(2-PHENYLPYRAZOL-3-YL)-1-[3- (TRIFLUOROMETHOXY)PHENYL]PYRIDAZIN-4-ONE
175, 1t9sA, 0.9578, 1.43, 0.387, 326, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A IN COMPLEX WITH GMP
176, 3tggA, 0.9575, 1.43, 0.390, 324, 313, A NOVEL SERIES OF POTENT AND SELECTIVE PDE5 INHIBITOR2
177, 3tgeA, 0.9575, 1.43, 0.390, 324, 313, A NOVEL SERIES OF POTENT AND SELECTIVE PDE5 INHIBITOR1
178, 3hc8A, 0.9574, 1.43, 0.390, 324, 313, INVESTIGATION OF AMINOPYRIDIOPYRAZINONES AS PDE5 INHIBITORS: EVALUATION OF MODIFICATIONS TO THE CENTRAL RING SYSTEM.
179, 4phwA, 0.9571, 0.73, 1.000, 305, 305, CRYSTAL STRUCTURE OF PDE10A WITH 1H-BENZIMIDAZOL-2-YL(4-((3- (TETRAHYDRO-2H-PYRAN-4-YL)-2-PYRIDINYL)OXY)PHENYL)METHANONE
180, 4phwB, 0.9570, 0.73, 1.000, 305, 305, CRYSTAL STRUCTURE OF PDE10A WITH 1H-BENZIMIDAZOL-2-YL(4-((3- (TETRAHYDRO-2H-PYRAN-4-YL)-2-PYRIDINYL)OXY)PHENYL)METHANONE
181, 1xp0A, 0.9569, 1.44, 0.387, 326, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A IN COMPLEX WITH VARDENAFIL
182, 3hqzA, 0.9558, 0.77, 0.964, 305, 305, DISCOVERY OF NOVEL INHIBITORS OF PDE10A
183, 3hr1A, 0.9555, 0.78, 0.964, 305, 305, DISCOVERY OF NOVEL INHIBITORS OF PDE10A
184, 2ovyA, 0.9553, 0.79, 0.964, 305, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF RAT PHOSPHODIESTERASE 10A
185, 3hqyA, 0.9552, 0.79, 0.964, 305, 305, DISCOVERY OF NOVEL INHIBITORS OF PDE10A
186, 3qpnA, 0.9551, 0.80, 0.964, 305, 305, STRUCTURE OF PDE10-INHIBITOR COMPLEX
187, 3qpoA, 0.9550, 0.80, 0.964, 305, 305, STRUCTURE OF PDE10-INHIBITOR COMPLEX
188, 4tppA, 0.9543, 0.82, 0.997, 305, 305, 2-(3-ALKOXY-1-AZETIDINYL) QUINOLINES AS NOVEL PDE10A INHIBITORS
189, 3qppA, 0.9540, 0.83, 0.964, 305, 305, STRUCTURE OF PDE10-INHIBITOR COMPLEX
190, 4xy2A, 0.9539, 0.60, 1.000, 312, 303, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH ASP9436
191, 2ovvA, 0.9524, 0.78, 0.967, 304, 304, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF RAT PHOSPHODIESTERASE 10A
192, 4fcdB, 0.9503, 0.62, 1.000, 310, 302, POTENT AND SELECTIVE PHOSPHODIESTERASE 10A INHIBITORS
193, 3snlB, 0.9503, 0.62, 1.000, 310, 302, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
194, 4tpmA, 0.9502, 0.75, 1.000, 303, 303, CRYSTAL STRUCTURE OF 2-(3-ALKOXY-1-AZETIDINYL) QUINOLINES AS PDE10A INHIBITORS
195, 3sn7B, 0.9502, 0.62, 1.000, 310, 302, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
196, 4fcbB, 0.9501, 0.63, 1.000, 310, 302, POTENT AND SELECTIVE PHOSPHODIESTERASE 10A INHIBITORS
197, 3sniB, 0.9491, 0.66, 1.000, 310, 302, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
198, 3hqwA, 0.9488, 0.80, 0.967, 303, 303, DISCOVERY OF NOVEL INHIBITORS OF PDE10A
199, 5xujA, 0.9470, 0.62, 1.000, 308, 301, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 7-(4-CHLOROPHENYL)-2- METHYLPYRAZOLO[15-A]PYRIMIDINE
200, 6b96B, 0.9434, 1.69, 0.351, 347, 313, CRYSTAL STRUCTURE OF PDE2 IN COMPLEX WITH COMPOUND 16
201, 4d08B, 0.9430, 1.72, 0.361, 337, 313, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
202, 5u00D, 0.9428, 1.72, 0.351, 336, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUORO-3-IODOPHENYL)CARBONYL]-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
203, 4c1iA, 0.9428, 1.70, 0.358, 325, 313, SELECTIVE INHIBITORS OF PDE2 PDE9 AND PDE10: MODULATORS OF ACTIVITY OF THE CENTRAL NERVOUS SYSTEM
204, 5u7kC, 0.9427, 1.71, 0.355, 339, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
205, 4d08A, 0.9426, 1.72, 0.358, 339, 313, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
206, 4jibA, 0.9422, 1.73, 0.355, 340, 313, CRYSTAL STRUCTURE OF OF PDE2-INHIBITOR COMPLEX
207, 6b97B, 0.9421, 1.71, 0.358, 348, 313, CRYSTAL STRUCTURE OF PDE2 IN COMPLEX WITH COMPLEX 9
208, 5tzaA, 0.9421, 1.73, 0.355, 341, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A WITH 3-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL-1-[(NAPHTHALENE-2-YL) CARBONYL]PIPERIDINE
209, 5tzwA, 0.9419, 1.74, 0.355, 342, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3 4-DIFLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
210, 5u7jA, 0.9418, 1.74, 0.355, 338, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
211, 4htzA, 0.9418, 1.73, 0.358, 338, 313, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN SPACE GROUP P1
212, 5tzcA, 0.9416, 1.74, 0.355, 343, 313, CRYSTAL STRUCTURE OF HUMAN PDE2A IN COMPLEX WITH (5S)-1-[(3-BROMO-4- FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[124]TRIAZOLO[15- A]PYRIMIDIN-7-YL}PIPERIDINE
213, 5u7dC, 0.9414, 1.74, 0.358, 338, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
214, 5tzhA, 0.9414, 1.75, 0.358, 341, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUOROPHENYL)CARBONYL]-5-{5-METHYL-[124]TRIAZOLO[1 5-A]PYRIMIDIN-7-YL}PIPERIDINE
215, 5tzcC, 0.9414, 1.75, 0.355, 340, 313, CRYSTAL STRUCTURE OF HUMAN PDE2A IN COMPLEX WITH (5S)-1-[(3-BROMO-4- FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[124]TRIAZOLO[15- A]PYRIMIDIN-7-YL}PIPERIDINE
216, 5u00A, 0.9413, 1.75, 0.355, 341, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUORO-3-IODOPHENYL)CARBONYL]-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
217, 3ituA, 0.9413, 1.75, 0.355, 338, 313, HPDE2A CATALYTIC DOMAIN COMPLEXED WITH IBMX
218, 5u7kA, 0.9412, 1.76, 0.358, 340, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
219, 6b96A, 0.9411, 1.67, 0.349, 343, 312, CRYSTAL STRUCTURE OF PDE2 IN COMPLEX WITH COMPOUND 16
220, 5tzzA, 0.9411, 1.75, 0.358, 342, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- BROMO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
221, 5u7lA, 0.9410, 1.75, 0.355, 339, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
222, 5u7iB, 0.9410, 1.77, 0.358, 336, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
223, 5u7kB, 0.9409, 1.74, 0.358, 343, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
224, 5u7iA, 0.9409, 1.76, 0.358, 338, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
225, 4d09B, 0.9409, 1.77, 0.361, 338, 313, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
226, 5tzxA, 0.9408, 1.76, 0.358, 342, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- CHLORO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
227, 4htxA, 0.9408, 1.75, 0.355, 338, 313, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN COMPLEX WITH BAY60-7550
228, 5tzxB, 0.9407, 1.78, 0.355, 337, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- CHLORO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
229, 5tzhB, 0.9407, 1.77, 0.355, 339, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUOROPHENYL)CARBONYL]-5-{5-METHYL-[124]TRIAZOLO[1 5-A]PYRIMIDIN-7-YL}PIPERIDINE
230, 5tzaB, 0.9407, 1.78, 0.355, 338, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A WITH 3-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL-1-[(NAPHTHALENE-2-YL) CARBONYL]PIPERIDINE
231, 5tz3B, 0.9407, 1.78, 0.355, 340, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH [12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}-N-(NAPHTHALENE-2-YL)PIPERIDINE-3- CARBOXAMIDE
232, 5u7jB, 0.9406, 1.78, 0.358, 336, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
233, 5tzwB, 0.9406, 1.78, 0.355, 339, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3 4-DIFLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
234, 5tz3A, 0.9406, 1.76, 0.361, 341, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH [12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}-N-(NAPHTHALENE-2-YL)PIPERIDINE-3- CARBOXAMIDE
235, 6b98B, 0.9405, 1.75, 0.358, 349, 313, PDE2 IN COMPLEX WITH COMPOUND 1
236, 5u7lC, 0.9405, 1.76, 0.355, 338, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
237, 5u00B, 0.9404, 1.78, 0.358, 339, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUORO-3-IODOPHENYL)CARBONYL]-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
238, 5tzcB, 0.9404, 1.78, 0.358, 343, 313, CRYSTAL STRUCTURE OF HUMAN PDE2A IN COMPLEX WITH (5S)-1-[(3-BROMO-4- FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[124]TRIAZOLO[15- A]PYRIMIDIN-7-YL}PIPERIDINE
239, 5tzzB, 0.9402, 1.79, 0.358, 339, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- BROMO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
240, 4htxB, 0.9402, 1.79, 0.358, 336, 313, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN COMPLEX WITH BAY60-7550
241, 4d09A, 0.9402, 1.76, 0.355, 340, 313, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
242, 4c1iB, 0.9402, 1.57, 0.358, 320, 310, SELECTIVE INHIBITORS OF PDE2 PDE9 AND PDE10: MODULATORS OF ACTIVITY OF THE CENTRAL NERVOUS SYSTEM
243, 5xkmC, 0.9401, 1.78, 0.355, 343, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
244, 5tzcD, 0.9399, 1.72, 0.353, 336, 312, CRYSTAL STRUCTURE OF HUMAN PDE2A IN COMPLEX WITH (5S)-1-[(3-BROMO-4- FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[124]TRIAZOLO[15- A]PYRIMIDIN-7-YL}PIPERIDINE
245, 5xkmB, 0.9397, 1.79, 0.351, 345, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
246, 5u00C, 0.9397, 1.78, 0.358, 339, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUORO-3-IODOPHENYL)CARBONYL]-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
247, 6b97A, 0.9393, 1.70, 0.349, 343, 312, CRYSTAL STRUCTURE OF PDE2 IN COMPLEX WITH COMPLEX 9
248, 5tzaD, 0.9390, 1.73, 0.353, 333, 312, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A WITH 3-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL-1-[(NAPHTHALENE-2-YL) CARBONYL]PIPERIDINE
249, 4jibD, 0.9387, 1.75, 0.353, 335, 312, CRYSTAL STRUCTURE OF OF PDE2-INHIBITOR COMPLEX
250, 4jibB, 0.9386, 1.82, 0.358, 336, 313, CRYSTAL STRUCTURE OF OF PDE2-INHIBITOR COMPLEX
251, 5xkmA, 0.9385, 1.82, 0.358, 340, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
252, 5u7dA, 0.9385, 1.80, 0.355, 338, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
253, 4htzB, 0.9384, 1.82, 0.358, 337, 313, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN SPACE GROUP P1
254, 5c1wB, 0.9378, 1.26, 1.000, 314, 304, PDE10 COMPLEXED WITH 46-DICHLORO-2-CYCLOPROPYL-5-METHYL-PYRIMIDINE
255, 5xkmD, 0.9376, 1.84, 0.351, 337, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
256, 5vp1A, 0.9376, 1.82, 0.358, 338, 313, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
257, 6b98A, 0.9374, 1.72, 0.359, 344, 312, PDE2 IN COMPLEX WITH COMPOUND 1
258, 5vp1B, 0.9373, 1.83, 0.355, 342, 313, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
259, 5tz3C, 0.9363, 1.84, 0.351, 334, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH [12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}-N-(NAPHTHALENE-2-YL)PIPERIDINE-3- CARBOXAMIDE
260, 4c1iC, 0.9361, 1.65, 0.358, 319, 310, SELECTIVE INHIBITORS OF PDE2 PDE9 AND PDE10: MODULATORS OF ACTIVITY OF THE CENTRAL NERVOUS SYSTEM
261, 3ituB, 0.9361, 1.81, 0.359, 333, 312, HPDE2A CATALYTIC DOMAIN COMPLEXED WITH IBMX
262, 5vp0B, 0.9358, 1.85, 0.358, 339, 313, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
263, 1z1lA, 0.9342, 1.97, 0.358, 338, 313, THE CRYSTAL STRUCTURE OF THE PHOSPHODIESTERASE 2A CATALYTIC DOMAIN
264, 5tzzD, 0.9337, 1.72, 0.355, 332, 310, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- BROMO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
265, 4c1iD, 0.9333, 1.69, 0.358, 319, 310, SELECTIVE INHIBITORS OF PDE2 PDE9 AND PDE10: MODULATORS OF ACTIVITY OF THE CENTRAL NERVOUS SYSTEM
266, 4d08D, 0.9324, 1.68, 0.356, 335, 309, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
267, 5vp0A, 0.9312, 1.94, 0.351, 334, 313, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
268, 4gh6B, 0.9282, 1.84, 0.263, 326, 308, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 28
269, 3qi3B, 0.9282, 1.72, 0.261, 325, 307, CRYSTAL STRUCTURE OF PDE9A(Q453E) IN COMPLEX WITH INHIBITOR BAY73-6691
270, 3n3zB, 0.9274, 1.74, 0.264, 326, 307, CRYSTAL STRUCTURE OF PDE9A (E406A) MUTANT IN COMPLEX WITH IBMX
271, 3jswB, 0.9272, 1.78, 0.264, 328, 307, HUMAN PDE9 IN COMPLEX WITH SELECTIVE INHIBITOR
272, 4e90B, 0.9269, 1.64, 0.265, 328, 306, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH INHIBITORS
273, 3k3hB, 0.9269, 1.51, 0.266, 320, 305, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH (S)- BAY73-6691
274, 4y8cB, 0.9266, 1.76, 0.264, 326, 307, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 9 IN COMPLEX WITH (S)-C33
275, 3qi4B, 0.9265, 1.77, 0.261, 325, 307, CRYSTAL STRUCTURE OF PDE9A(Q453E) IN COMPLEX WITH IBMX
276, 2hd1B, 0.9264, 1.77, 0.264, 326, 307, CRYSTAL STRUCTURE OF PDE9 IN COMPLEX WITH IBMX
277, 3dy8B, 0.9263, 1.80, 0.264, 328, 307, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH PRODUCT 5 -GMP (E+P COMPLEX)
278, 3dysB, 0.9261, 1.79, 0.264, 328, 307, HUMAN PHOSPHODIESTRASE-5 GMP COMPLEX (EP) PRODUCED BY SOAKING WITH 20MM CGMP+20 MM MNCL2+20 MM MGCL2 FOR 2 HOURS AND FLASH-COOLED TO LIQUID NITROGEN TEMPERATURE WHEN SUBSTRATE WAS STILL ABUDANT.
279, 4y86B, 0.9260, 1.77, 0.264, 326, 307, CRYSTAL STRUCTURE OF PDE9 IN COMPLEX WITH RACEMIC INHIBITOR C33
280, 4g2jB, 0.9257, 1.66, 0.265, 328, 306, HUMAN PDE9 IN COMPLEX WITH SELECTIVE COMPOUND
281, 2yy2B, 0.9257, 1.77, 0.264, 324, 307, CRYSTAL STRUCTURE OF THE HUMAN PHOSPHODIESTERASE 9A CATALYTIC DOMAIN COMPLEXED WITH IBMX
282, 4g2lB, 0.9256, 1.66, 0.265, 328, 306, HUMAN PDE9 IN COMPLEX WITH SELECTIVE COMPOUND
283, 3dynB, 0.9256, 1.66, 0.265, 328, 306, HUMAN PHOSPHODIESTRASE 9 IN COMPLEX WITH CGMP (ZN INHIBITED)
284, 3jsiB, 0.9255, 1.66, 0.265, 328, 306, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH INHIBITOR
285, 4y87B, 0.9254, 1.78, 0.264, 326, 307, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 9 IN COMPLEX WITH (R)-C33 (6- {[(1R)-1-(4-CHLOROPHENYL)ETHYL]AMINO}-1-CYCLOPENTYL-15-DIHYDRO-4H- PYRAZOLO[34-D]PYRIMIDIN-4-ONE)
286, 3dyqB, 0.9251, 1.67, 0.265, 328, 306, HUMAN PHOSPHODIESTRASE 9 (INHIBITED BY OMITTING DIVALENT CATION) IN COMPLEX WITH CGMP
287, 3qi3A, 0.9250, 1.80, 0.261, 325, 307, CRYSTAL STRUCTURE OF PDE9A(Q453E) IN COMPLEX WITH INHIBITOR BAY73-6691
288, 3k3eB, 0.9250, 1.48, 0.266, 319, 304, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH (R)- BAY73-6691
289, 4gh6A, 0.9249, 1.80, 0.264, 326, 307, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 28
290, 4e90A, 0.9247, 1.69, 0.265, 328, 306, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH INHIBITORS
291, 3n3zA, 0.9247, 1.82, 0.264, 326, 307, CRYSTAL STRUCTURE OF PDE9A (E406A) MUTANT IN COMPLEX WITH IBMX
292, 3dylB, 0.9245, 1.68, 0.265, 328, 306, HUMAN PHOSPHDIESTERASE 9 SUBSTRATE COMPLEX (ES COMPLEX)
293, 4y8cA, 0.9244, 1.70, 0.265, 322, 306, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 9 IN COMPLEX WITH (S)-C33
294, 3jsiA, 0.9244, 1.70, 0.265, 328, 306, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH INHIBITOR
295, 2r8qB, 0.9242, 1.87, 0.276, 335, 312, STRUCTURE OF LMJPDEB1 IN COMPLEX WITH IBMX
296, 3dysA, 0.9241, 1.81, 0.264, 324, 307, HUMAN PHOSPHODIESTRASE-5 GMP COMPLEX (EP) PRODUCED BY SOAKING WITH 20MM CGMP+20 MM MNCL2+20 MM MGCL2 FOR 2 HOURS AND FLASH-COOLED TO LIQUID NITROGEN TEMPERATURE WHEN SUBSTRATE WAS STILL ABUDANT.
297, 3qi4A, 0.9240, 1.83, 0.261, 325, 307, CRYSTAL STRUCTURE OF PDE9A(Q453E) IN COMPLEX WITH IBMX
298, 3jswA, 0.9240, 1.70, 0.265, 328, 306, HUMAN PDE9 IN COMPLEX WITH SELECTIVE INHIBITOR
299, 2yy2A, 0.9240, 1.82, 0.264, 326, 307, CRYSTAL STRUCTURE OF THE HUMAN PHOSPHODIESTERASE 9A CATALYTIC DOMAIN COMPLEXED WITH IBMX
300, 4y87A, 0.9239, 1.71, 0.265, 322, 306, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 9 IN COMPLEX WITH (R)-C33 (6- {[(1R)-1-(4-CHLOROPHENYL)ETHYL]AMINO}-1-CYCLOPENTYL-15-DIHYDRO-4H- PYRAZOLO[34-D]PYRIMIDIN-4-ONE)
301, 4g2lA, 0.9239, 1.70, 0.265, 328, 306, HUMAN PDE9 IN COMPLEX WITH SELECTIVE COMPOUND
302, 4g2jA, 0.9239, 1.70, 0.265, 328, 306, HUMAN PDE9 IN COMPLEX WITH SELECTIVE COMPOUND
303, 2hd1A, 0.9239, 1.83, 0.264, 326, 307, CRYSTAL STRUCTURE OF PDE9 IN COMPLEX WITH IBMX
304, 4qgeB, 0.9238, 1.69, 0.265, 320, 306, PHOSPHODIESTERASE-9A IN COMPLEX WITH INHIBITOR WYQ-C36D
305, 4y86A, 0.9237, 1.71, 0.265, 322, 306, CRYSTAL STRUCTURE OF PDE9 IN COMPLEX WITH RACEMIC INHIBITOR C33
306, 4d09C, 0.9236, 1.80, 0.354, 329, 308, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
307, 4qgeA, 0.9235, 1.72, 0.265, 322, 306, PHOSPHODIESTERASE-9A IN COMPLEX WITH INHIBITOR WYQ-C36D
308, 3dy8A, 0.9233, 1.71, 0.265, 328, 306, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH PRODUCT 5 -GMP (E+P COMPLEX)
309, 3dylA, 0.9227, 1.72, 0.265, 328, 306, HUMAN PHOSPHDIESTERASE 9 SUBSTRATE COMPLEX (ES COMPLEX)
310, 3dyqA, 0.9225, 1.72, 0.265, 328, 306, HUMAN PHOSPHODIESTRASE 9 (INHIBITED BY OMITTING DIVALENT CATION) IN COMPLEX WITH CGMP
311, 4d08C, 0.9224, 1.71, 0.353, 327, 306, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
312, 5u7jD, 0.9223, 1.72, 0.353, 327, 306, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
313, 4nw7A, 0.9223, 2.11, 0.244, 344, 312, PDE4 CATALYTIC DOMAIN
314, 5tzaC, 0.9222, 1.77, 0.355, 328, 307, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A WITH 3-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL-1-[(NAPHTHALENE-2-YL) CARBONYL]PIPERIDINE
315, 3k3hA, 0.9222, 1.60, 0.266, 320, 305, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH (S)- BAY73-6691
316, 3ituD, 0.9222, 1.72, 0.356, 327, 306, HPDE2A CATALYTIC DOMAIN COMPLEXED WITH IBMX
317, 5u7jC, 0.9220, 1.74, 0.356, 327, 306, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
318, 5tzwD, 0.9219, 1.72, 0.353, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3 4-DIFLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
319, 5tzhD, 0.9219, 1.72, 0.353, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUOROPHENYL)CARBONYL]-5-{5-METHYL-[124]TRIAZOLO[1 5-A]PYRIMIDIN-7-YL}PIPERIDINE
320, 3g45A, 0.9219, 2.03, 0.244, 371, 311, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4B WITH REGULATORY DOMAIN AND D155988
321, 3dynA, 0.9218, 1.74, 0.265, 328, 306, HUMAN PHOSPHODIESTRASE 9 IN COMPLEX WITH CGMP (ZN INHIBITED)
322, 5tzwC, 0.9216, 1.79, 0.355, 328, 307, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3 4-DIFLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
323, 4htxD, 0.9215, 1.73, 0.356, 327, 306, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN COMPLEX WITH BAY60-7550
324, 5u7iD, 0.9214, 1.73, 0.356, 324, 306, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
325, 3g45B, 0.9214, 1.93, 0.245, 370, 310, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4B WITH REGULATORY DOMAIN AND D155988
326, 2r8qA, 0.9214, 1.92, 0.279, 335, 312, STRUCTURE OF LMJPDEB1 IN COMPLEX WITH IBMX
327, 5u7kD, 0.9213, 1.73, 0.353, 327, 306, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
328, 5tz3D, 0.9212, 1.73, 0.353, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH [12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}-N-(NAPHTHALENE-2-YL)PIPERIDINE-3- CARBOXAMIDE
329, 2ouuB, 0.9212, 1.57, 0.997, 312, 303, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A IN COMPLEX WITH CGMP
330, 5tzxD, 0.9211, 1.74, 0.353, 328, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- CHLORO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
331, 4d09D, 0.9209, 1.73, 0.356, 326, 306, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
332, 3k3eA, 0.9204, 1.58, 0.266, 319, 304, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH (R)- BAY73-6691
333, 4jibC, 0.9203, 1.76, 0.353, 327, 306, CRYSTAL STRUCTURE OF OF PDE2-INHIBITOR COMPLEX
334, 5laqA, 0.9199, 2.05, 0.244, 337, 311, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4B CATALYTIC DOMAIN WITH INHIBITOR NPD-001
335, 4htzD, 0.9199, 1.71, 0.361, 326, 305, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN SPACE GROUP P1
336, 3ituC, 0.9199, 1.77, 0.356, 327, 306, HPDE2A CATALYTIC DOMAIN COMPLEXED WITH IBMX
337, 2ouqB, 0.9199, 1.34, 1.000, 309, 299, CRYSTAL STRUCTURE OF PDE10A2 IN COMPLEX WITH GMP
338, 5u7iC, 0.9198, 1.77, 0.359, 327, 306, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
339, 1ptwD, 0.9195, 2.30, 0.240, 334, 313, THE CRYSTAL STRUCTURE OF AMP-BOUND PDE4 SUGGESTS A MECHANISM FOR PHOSPHODIESTERASE CATALYSIS
340, 5ohjA, 0.9194, 2.08, 0.244, 336, 311, HUMAN PHOSPHODIESTERASE 4B CATALYTIC DOMAIN IN COMPLEX WITH A PYRROLIDINYL INHIBITOR.
341, 2h42A, 0.9194, 1.75, 0.401, 326, 304, CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH SILDENAFIL
342, 5tzzC, 0.9192, 1.78, 0.359, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- BROMO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
343, 4myqA, 0.9192, 2.28, 0.240, 345, 313, SELECTIVE INHIBITION OF THE CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B WITH A-33
344, 4htxC, 0.9192, 1.72, 0.357, 325, 305, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN COMPLEX WITH BAY60-7550
345, 2qykB, 0.9191, 2.00, 0.248, 335, 310, CRYSTAL STRUCTURE OF PDE4A10 IN COMPLEX WITH INHIBITOR NPV
346, 1ro6A, 0.9190, 2.29, 0.239, 344, 314, CRYSTAL STRUCTURE OF PDE4B2B COMPLEXED WITH ROLIPRAM (R & S)
347, 5tzhC, 0.9189, 1.79, 0.356, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUOROPHENYL)CARBONYL]-5-{5-METHYL-[124]TRIAZOLO[1 5-A]PYRIMIDIN-7-YL}PIPERIDINE
348, 3g4lD, 0.9187, 2.15, 0.240, 334, 312, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROFLUMILAST
349, 1q9mD, 0.9186, 2.29, 0.240, 334, 313, THREE DIMENSIONAL STRUCTURES OF PDE4D IN COMPLEX WITH ROLIPRAMS AND IMPLICATION ON INHIBITOR SELECTIVITY
350, 1oynD, 0.9185, 2.29, 0.240, 334, 313, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH (RS)-ROLIPRAM
351, 3g4iD, 0.9184, 2.31, 0.240, 334, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155871
352, 1zknD, 0.9182, 2.30, 0.240, 334, 313, STRUCTURE OF PDE4D2-IBMX
353, 5tzxC, 0.9181, 1.80, 0.356, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- CHLORO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
354, 4htzC, 0.9180, 1.75, 0.357, 325, 305, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN SPACE GROUP P1
355, 2fm5D, 0.9179, 2.30, 0.240, 334, 313, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR L- 869299
356, 3g58D, 0.9177, 2.16, 0.240, 345, 312, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155988/PMNPQ
357, 2fm0D, 0.9177, 2.30, 0.240, 334, 313, CRYSTAL STRUCTURE OF PDE4D IN COMPLEX WITH L-869298
358, 3hmvA, 0.9176, 2.22, 0.240, 351, 312, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A TETRAHYDROBENZOTHIOPHENE INHIBITOR
359, 3tvxA, 0.9175, 1.95, 0.249, 334, 309, THE STRUCTURE OF PDE4A WITH PENTOXIFYLLINE AT 2.84A RESOLUTION
360, 3hmvB, 0.9175, 2.23, 0.240, 351, 312, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A TETRAHYDROBENZOTHIOPHENE INHIBITOR
361, 1ro6B, 0.9173, 2.35, 0.236, 344, 314, CRYSTAL STRUCTURE OF PDE4B2B COMPLEXED WITH ROLIPRAM (R & S)
362, 1uhoA, 0.9171, 1.89, 0.398, 313, 304, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 5 COMPLEXED WITH VARDENAFIL(LEVITRA)
363, 2ouyB, 0.9169, 1.43, 0.997, 309, 299, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D564A IN COMPLEX WITH CAMP.
364, 3i8vA, 0.9168, 2.04, 0.248, 334, 310, CRYSTAL STRUCTURE OF HUMAN PDE4A WITH 4-(3-BUTOXY-4-METHOXYPHENYL) METHYL-2-IMIDAZOLIDONE
365, 3g4kD, 0.9168, 2.24, 0.240, 333, 312, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROLIPRAM
366, 2qykA, 0.9167, 1.94, 0.249, 334, 309, CRYSTAL STRUCTURE OF PDE4A10 IN COMPLEX WITH INHIBITOR NPV
367, 2qylA, 0.9166, 2.08, 0.245, 335, 310, CRYSTAL STRUCTURE OF PDE4B2B IN COMPLEX WITH INHIBITOR NPV
368, 1udtA, 0.9160, 1.89, 0.398, 313, 304, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 5 COMPLEXED WITH SILDENAFIL(VIAGRA)
369, 6fdcA, 0.9159, 2.17, 0.242, 329, 310, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 32A 
370, 5wqaB, 0.9159, 2.24, 0.242, 334, 310, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN COMPLEXED WITH SELAGINPULVILINS K
371, 1ro9A, 0.9159, 2.39, 0.239, 338, 314, CRYSTAL STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHODIESTERASE 4B2B COMPLEXED WITH 8-BR-AMP
372, 5wqaA, 0.9157, 2.26, 0.242, 334, 310, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN COMPLEXED WITH SELAGINPULVILINS K
373, 5c28B, 0.9157, 1.88, 0.993, 317, 302, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-5-METHYL-PYRIMIDIN-4-AMINE
374, 1f0jA, 0.9156, 2.39, 0.239, 351, 314, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B
375, 6f8tA, 0.9155, 2.18, 0.245, 328, 310, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 4A 
376, 5ohjB, 0.9153, 2.02, 0.245, 335, 310, HUMAN PHOSPHODIESTERASE 4B CATALYTIC DOMAIN IN COMPLEX WITH A PYRROLIDINYL INHIBITOR.
377, 3tvxB, 0.9153, 1.99, 0.249, 334, 309, THE STRUCTURE OF PDE4A WITH PENTOXIFYLLINE AT 2.84A RESOLUTION
378, 3ly2B, 0.9153, 2.17, 0.241, 345, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
379, 6f8wB, 0.9149, 2.22, 0.242, 331, 310, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 18A 
380, 1rorA, 0.9149, 2.30, 0.240, 338, 313, CRYSTAL STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHODIESTERASE 4B2B COMPLEXED WITH AMP
381, 2h42B, 0.9148, 1.82, 0.401, 317, 304, CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH SILDENAFIL
382, 1ptwA, 0.9146, 2.34, 0.238, 334, 311, THE CRYSTAL STRUCTURE OF AMP-BOUND PDE4 SUGGESTS A MECHANISM FOR PHOSPHODIESTERASE CATALYSIS
383, 6f6uA, 0.9145, 2.23, 0.245, 328, 310, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 7B 
384, 1so2C, 0.9145, 1.70, 0.220, 372, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR
385, 2h42C, 0.9144, 1.64, 0.397, 317, 302, CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH SILDENAFIL
386, 3ly2A, 0.9142, 2.19, 0.241, 345, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
387, 2ourB, 0.9141, 1.50, 0.997, 315, 299, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A IN COMPLEX WITH CAMP
388, 1uduB, 0.9140, 1.97, 0.398, 313, 304, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 5 COMPLEXED WITH TADALAFIL(CIALIS)
389, 1uduA, 0.9140, 1.97, 0.398, 313, 304, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 5 COMPLEXED WITH TADALAFIL(CIALIS)
390, 3i8vB, 0.9139, 2.00, 0.249, 333, 309, CRYSTAL STRUCTURE OF HUMAN PDE4A WITH 4-(3-BUTOXY-4-METHOXYPHENYL) METHYL-2-IMIDAZOLIDONE
391, 3d3pA, 0.9139, 2.26, 0.241, 336, 311, CRYSTAL STRUCTURE OF PDE4B CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIDINE INHIBITOR
392, 5l9hB, 0.9137, 2.06, 0.277, 334, 311, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-340
393, 3o57A, 0.9137, 2.27, 0.241, 336, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A 5- HETEROCYCLE PYRAZOLOPYRIDINE INHIBITOR
394, 4phlB, 0.9135, 2.05, 0.280, 332, 311, TBRPDEB1-INHIBITOR COMPLEX
395, 2qynA, 0.9135, 1.96, 0.245, 326, 306, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR NPV
396, 3gwtA, 0.9134, 2.27, 0.241, 336, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A QUINOLINE INHIBITOR
397, 1xorB, 0.9132, 1.92, 0.245, 327, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ZARDAVERINE
398, 6f8vA, 0.9131, 2.17, 0.246, 327, 309, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 18B 
399, 3o56A, 0.9131, 2.41, 0.240, 335, 312, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A 5- HETEROCYCLE PYRAZOLOPYRIDINE INHIBITOR
400, 3frgA, 0.9131, 2.27, 0.241, 335, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A QUINOLINE INHIBITOR
401, 1tbbB, 0.9130, 1.92, 0.245, 326, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ROLIPRAM
402, 5g2bA, 0.9129, 2.06, 0.277, 333, 311, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-008
403, 2pw3A, 0.9129, 1.90, 0.242, 327, 306, STRUCTURE OF THE PDE4D-CAMP COMPLEX
404, 3v9bB, 0.9128, 2.05, 0.244, 327, 307, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH (S)-N-(3-{1- [1-(3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXYPHENYL)-2-(1-OXYPYRIDIN-4- YL)-ETHYL]-1H-PYRAZL-3-YL}PHENYL)ACETAMIDE
405, 5l8cA, 0.9127, 2.07, 0.277, 333, 311, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-039
406, 5wh6A, 0.9126, 1.99, 0.245, 326, 306, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR (S_ZL-N-91) 
407, 5l8yA, 0.9125, 2.07, 0.277, 333, 311, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-937
408, 5g57A, 0.9123, 2.07, 0.277, 333, 311, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
409, 4x0fA, 0.9123, 2.25, 0.244, 411, 311, CRYSTAL STRUCTURE OF CROSSLINK STABILIZED LONG-FORM PDE4B IN COMPLEX WITH (R)-(-)-ROLIPRAM
410, 5h2qA, 0.9122, 1.93, 0.298, 329, 309, CRYSTAL STRUCTURE OF T BRUCEI PHOSPHODIESTERASE B2 BOUND TO COMPOUND 13E
411, 3g4gA, 0.9122, 1.93, 0.245, 338, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH REGULATORY DOMAIN AND D155871
412, 1y2cA, 0.9122, 1.87, 0.246, 326, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
413, 1rorB, 0.9122, 2.38, 0.240, 337, 313, CRYSTAL STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHODIESTERASE 4B2B COMPLEXED WITH AMP
414, 5k1iA, 0.9121, 1.87, 0.246, 322, 305, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
415, 5h2rA, 0.9121, 1.94, 0.301, 329, 309, CRYSTAL STRUCTURE OF T BRUCEI PHOSPHODIESTERASE B2 BOUND TO COMPOUND 15B
416, 3v9bA, 0.9121, 2.13, 0.244, 331, 308, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH (S)-N-(3-{1- [1-(3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXYPHENYL)-2-(1-OXYPYRIDIN-4- YL)-ETHYL]-1H-PYRAZL-3-YL}PHENYL)ACETAMIDE
417, 1zknA, 0.9121, 2.40, 0.241, 334, 311, STRUCTURE OF PDE4D2-IBMX
418, 5wh5A, 0.9120, 2.00, 0.245, 326, 306, CRYSTAL STRUCTURE OF THE PDE4D2 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR (R)-ZL-N-91 
419, 1y2bA, 0.9120, 1.88, 0.246, 326, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
420, 5wh6B, 0.9119, 1.95, 0.245, 325, 306, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR (S_ZL-N-91) 
421, 1oynA, 0.9119, 2.17, 0.243, 334, 309, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH (RS)-ROLIPRAM
422, 5l8yB, 0.9118, 2.03, 0.277, 332, 310, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-937
423, 5g5vB, 0.9118, 2.08, 0.277, 332, 311, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-038
424, 4i15A, 0.9118, 2.07, 0.277, 333, 311, CRYSTAL STRUCTURE OF TBRPDEB1
425, 3g4gD, 0.9118, 1.94, 0.245, 337, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH REGULATORY DOMAIN AND D155871
426, 1y2dA, 0.9118, 1.88, 0.246, 326, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 1-(4- METHOXY-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
427, 1tb7B, 0.9118, 1.89, 0.246, 326, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH AMP
428, 6f8xB, 0.9117, 1.94, 0.252, 324, 305, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 26G 
429, 5l8cB, 0.9117, 2.04, 0.277, 332, 310, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-039
430, 6fdcB, 0.9116, 1.95, 0.249, 324, 305, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 32A 
431, 5wh5B, 0.9115, 1.95, 0.245, 325, 306, CRYSTAL STRUCTURE OF THE PDE4D2 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR (R)-ZL-N-91 
432, 3g4gC, 0.9115, 1.95, 0.245, 339, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH REGULATORY DOMAIN AND D155871
433, 1y2eA, 0.9115, 1.89, 0.246, 326, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 1-(4- AMINO-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
434, 1y2kA, 0.9114, 1.89, 0.246, 326, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1-(3-NITRO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
435, 1xomA, 0.9114, 1.90, 0.246, 326, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH CILOMILAST
436, 4i15B, 0.9113, 2.09, 0.277, 333, 311, CRYSTAL STRUCTURE OF TBRPDEB1
437, 5l9hA, 0.9112, 2.09, 0.277, 333, 311, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-340
438, 1y2cB, 0.9112, 1.89, 0.246, 326, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
439, 1xoqA, 0.9112, 1.90, 0.246, 326, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ROFLUMILAST
440, 1mkdH, 0.9112, 2.10, 0.244, 328, 307, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
441, 1mkdA, 0.9112, 2.10, 0.244, 328, 307, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
442, 6f8tB, 0.9111, 1.97, 0.252, 324, 305, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 4A 
443, 5k1iG, 0.9111, 1.91, 0.246, 322, 305, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
444, 2qynB, 0.9111, 1.95, 0.245, 325, 306, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR NPV
445, 1y2bB, 0.9111, 1.90, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
446, 1mkdG, 0.9111, 2.10, 0.244, 328, 307, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
447, 1mkdB, 0.9111, 2.10, 0.244, 328, 307, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
448, 5vydA, 0.9109, 1.72, 0.261, 314, 303, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE DOMAIN OF RHOPDE FUSION PROTEIN FROM THE CHOANOFLAGELLATE SALPINGOECA ROSETTA
449, 5k1iD, 0.9108, 1.91, 0.246, 326, 305, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
450, 1xonB, 0.9108, 1.90, 0.246, 326, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH PICLAMILAST
451, 1tb7A, 0.9108, 1.90, 0.246, 321, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH AMP
452, 6f6uB, 0.9107, 1.97, 0.249, 324, 305, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 7B 
453, 1ro9B, 0.9106, 2.41, 0.240, 337, 313, CRYSTAL STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHODIESTERASE 4B2B COMPLEXED WITH 8-BR-AMP
454, 1mkdK, 0.9106, 1.98, 0.245, 328, 306, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
455, 1mkdJ, 0.9106, 1.98, 0.245, 328, 306, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
456, 1mkdE, 0.9106, 1.98, 0.245, 328, 306, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
457, 1mkdD, 0.9106, 1.98, 0.245, 328, 306, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
458, 6f8vB, 0.9105, 1.96, 0.249, 324, 305, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 18B 
459, 6f8uB, 0.9105, 1.97, 0.249, 325, 305, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 20B 
460, 6f8rB, 0.9105, 1.96, 0.249, 324, 305, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 54 
461, 1y2kB, 0.9105, 1.91, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1-(3-NITRO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
462, 1y2dB, 0.9105, 1.90, 0.246, 326, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 1-(4- METHOXY-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
463, 1tbbA, 0.9105, 1.90, 0.246, 321, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ROLIPRAM
464, 1ptwB, 0.9105, 2.00, 0.242, 327, 306, THE CRYSTAL STRUCTURE OF AMP-BOUND PDE4 SUGGESTS A MECHANISM FOR PHOSPHODIESTERASE CATALYSIS
465, 1mkdL, 0.9105, 1.98, 0.245, 328, 306, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
466, 1mkdI, 0.9105, 1.98, 0.245, 328, 306, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
467, 1mkdC, 0.9105, 1.98, 0.245, 328, 306, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
468, 5g5vA, 0.9104, 2.06, 0.277, 335, 310, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-038
469, 3v9bD, 0.9104, 2.09, 0.244, 326, 307, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH (S)-N-(3-{1- [1-(3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXYPHENYL)-2-(1-OXYPYRIDIN-4- YL)-ETHYL]-1H-PYRAZL-3-YL}PHENYL)ACETAMIDE
470, 3g4gB, 0.9104, 1.93, 0.252, 336, 305, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH REGULATORY DOMAIN AND D155871
471, 1y2eB, 0.9104, 1.90, 0.246, 320, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 1-(4- AMINO-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
472, 1xoqB, 0.9104, 1.91, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ROFLUMILAST
473, 1mkdF, 0.9104, 1.98, 0.245, 328, 306, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
474, 3sl4B, 0.9103, 1.96, 0.245, 325, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10D
475, 1xorA, 0.9103, 1.91, 0.246, 321, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ZARDAVERINE
476, 3v9bC, 0.9102, 1.98, 0.245, 325, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH (S)-N-(3-{1- [1-(3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXYPHENYL)-2-(1-OXYPYRIDIN-4- YL)-ETHYL]-1H-PYRAZL-3-YL}PHENYL)ACETAMIDE
477, 3sl5B, 0.9102, 1.97, 0.245, 325, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 COMPLEXED WITH COMPOUND 10D
478, 2fm0A, 0.9102, 2.09, 0.244, 334, 308, CRYSTAL STRUCTURE OF PDE4D IN COMPLEX WITH L-869298
479, 1xonA, 0.9102, 1.92, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH PICLAMILAST
480, 1xomB, 0.9102, 1.92, 0.246, 321, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH CILOMILAST
481, 1q9mA, 0.9102, 2.10, 0.244, 334, 308, THREE DIMENSIONAL STRUCTURES OF PDE4D IN COMPLEX WITH ROLIPRAMS AND IMPLICATION ON INHIBITOR SELECTIVITY
482, 5h2rB, 0.9100, 1.88, 0.296, 328, 307, CRYSTAL STRUCTURE OF T BRUCEI PHOSPHODIESTERASE B2 BOUND TO COMPOUND 15B
483, 3v93G, 0.9100, 2.11, 0.197, 334, 309, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
484, 4phlA, 0.9099, 2.03, 0.282, 330, 309, TBRPDEB1-INHIBITOR COMPLEX
485, 5lboB, 0.9098, 1.97, 0.245, 324, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D2 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
486, 2fm5A, 0.9098, 2.09, 0.244, 334, 308, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR L- 869299
487, 3g58A, 0.9097, 2.27, 0.246, 335, 309, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155988/PMNPQ
488, 5k1iE, 0.9096, 1.92, 0.246, 321, 305, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
489, 3sl6B, 0.9096, 1.97, 0.245, 325, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 12C
490, 3iadB, 0.9096, 1.97, 0.245, 338, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH BOUND ALLOSTERIC MODULATOR
491, 2pw3B, 0.9095, 1.97, 0.242, 325, 306, STRUCTURE OF THE PDE4D-CAMP COMPLEX
492, 5k1iH, 0.9094, 1.92, 0.246, 326, 305, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
493, 5g57B, 0.9094, 2.08, 0.277, 332, 310, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
494, 5g2bB, 0.9094, 2.07, 0.277, 332, 310, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-008
495, 6f8wA, 0.9093, 1.79, 0.251, 322, 303, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 18A 
496, 5k1iF, 0.9093, 1.90, 0.246, 326, 305, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
497, 5tkbA, 0.9092, 2.18, 0.244, 326, 308, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH A TETRAFLUORANLINE COMPOUND
498, 5h2qB, 0.9091, 1.89, 0.296, 328, 307, CRYSTAL STRUCTURE OF T BRUCEI PHOSPHODIESTERASE B2 BOUND TO COMPOUND 13E
499, 4kp6A, 0.9091, 1.95, 0.246, 324, 305, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4B (PDE4B) IN COMPLEX WITH A [135]TRIAZINE DERIVATIVE
500, 1q9mB, 0.9091, 2.12, 0.241, 327, 307, THREE DIMENSIONAL STRUCTURES OF PDE4D IN COMPLEX WITH ROLIPRAMS AND IMPLICATION ON INHIBITOR SELECTIVITY
501, 5lboA, 0.9090, 2.12, 0.244, 330, 307, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D2 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
502, 5k1iB, 0.9090, 1.93, 0.246, 326, 305, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
503, 3v93F, 0.9090, 2.12, 0.197, 334, 309, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
504, 3sl4A, 0.9090, 2.01, 0.245, 329, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10D
505, 3ly2C, 0.9090, 2.35, 0.241, 332, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
506, 5k1iC, 0.9089, 1.94, 0.246, 321, 305, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
507, 3ly2G, 0.9089, 2.31, 0.241, 332, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
508, 3g4lB, 0.9089, 2.00, 0.245, 326, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROFLUMILAST
509, 3ly2H, 0.9088, 2.31, 0.241, 332, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
510, 1oynB, 0.9088, 2.01, 0.245, 327, 306, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH (RS)-ROLIPRAM
511, 3sl8B, 0.9084, 2.08, 0.252, 324, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10O
512, 3g4iA, 0.9084, 2.08, 0.244, 331, 307, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155871
513, 1tb5A, 0.9084, 1.96, 0.246, 323, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH AMP
514, 5tkbD, 0.9083, 1.99, 0.245, 325, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH A TETRAFLUORANLINE COMPOUND
515, 1xmuA, 0.9083, 2.15, 0.247, 329, 308, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH ROFLUMILAST
516, 1f0jB, 0.9083, 2.33, 0.240, 337, 312, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B
517, 1ptwC, 0.9082, 2.05, 0.245, 327, 306, THE CRYSTAL STRUCTURE OF AMP-BOUND PDE4 SUGGESTS A MECHANISM FOR PHOSPHODIESTERASE CATALYSIS
518, 3g58B, 0.9080, 2.11, 0.244, 327, 307, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155988/PMNPQ
519, 3g4iB, 0.9080, 2.00, 0.245, 326, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155871
520, 3g4lA, 0.9078, 2.05, 0.245, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROFLUMILAST
521, 3sl5D, 0.9077, 1.94, 0.246, 324, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 COMPLEXED WITH COMPOUND 10D
522, 3g4kB, 0.9076, 2.00, 0.245, 326, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROLIPRAM
523, 1oynC, 0.9076, 2.02, 0.245, 327, 306, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH (RS)-ROLIPRAM
524, 6f8xA, 0.9075, 1.92, 0.250, 322, 304, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 26G 
525, 5tkbC, 0.9075, 2.02, 0.245, 323, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH A TETRAFLUORANLINE COMPOUND
526, 5lboD, 0.9075, 1.95, 0.246, 324, 305, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D2 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
527, 5lboC, 0.9075, 1.94, 0.246, 323, 305, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D2 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
528, 3v93C, 0.9075, 2.04, 0.198, 333, 308, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
529, 3sl5A, 0.9075, 2.08, 0.245, 328, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 COMPLEXED WITH COMPOUND 10D
530, 6f8rA, 0.9074, 1.94, 0.250, 322, 304, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 54 
531, 4w1oB, 0.9074, 2.05, 0.245, 325, 306, PDE4D COMPLEXED WITH INHIBITOR
532, 1xotB, 0.9074, 2.00, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH VARDENAFIL
533, 3sl4D, 0.9073, 1.95, 0.246, 324, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10D
534, 3iadD, 0.9073, 2.02, 0.245, 339, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH BOUND ALLOSTERIC MODULATOR
535, 3g4iC, 0.9073, 2.02, 0.245, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155871
536, 3sl8D, 0.9071, 1.96, 0.246, 324, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10O
537, 1zknB, 0.9071, 2.03, 0.245, 327, 306, STRUCTURE OF PDE4D2-IBMX
538, 1tb5B, 0.9071, 1.97, 0.246, 323, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH AMP
539, 1sojL, 0.9071, 1.83, 0.221, 381, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
540, 1sojJ, 0.9071, 1.83, 0.221, 381, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
541, 1sojH, 0.9071, 1.83, 0.221, 381, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
542, 1sojF, 0.9071, 1.83, 0.221, 381, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
543, 1sojD, 0.9071, 1.83, 0.221, 381, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
544, 1sojB, 0.9071, 1.83, 0.221, 381, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
545, 6f8uA, 0.9070, 1.92, 0.250, 322, 304, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 20B 
546, 4ogbD, 0.9070, 1.96, 0.246, 324, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 2
547, 3ly2E, 0.9070, 2.21, 0.243, 329, 309, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
548, 2fm0B, 0.9070, 2.14, 0.244, 327, 307, CRYSTAL STRUCTURE OF PDE4D IN COMPLEX WITH L-869298
549, 3g4kA, 0.9069, 2.04, 0.245, 330, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROLIPRAM
550, 3sl3D, 0.9068, 1.96, 0.246, 324, 305, CRYSTAL STRUCTURE OF THE APO FORM OF THE CATALYTIC DOMAIN OF PDE4D2
551, 3o0jA, 0.9068, 1.92, 0.247, 323, 304, PDE4B IN COMPLEX WITH LIGAND AN2898
552, 3w5eB, 0.9067, 2.38, 0.241, 345, 311, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 4B IN COMPLEX WITH COMPOUND 31E
553, 3ly2F, 0.9067, 2.20, 0.244, 329, 308, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
554, 1zknC, 0.9067, 2.03, 0.245, 330, 306, STRUCTURE OF PDE4D2-IBMX
555, 3g4lC, 0.9066, 1.97, 0.246, 326, 305, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROFLUMILAST
556, 2fm0C, 0.9066, 2.03, 0.242, 327, 306, CRYSTAL STRUCTURE OF PDE4D IN COMPLEX WITH L-869298
557, 5k6jA, 0.9065, 1.93, 0.247, 323, 304, HUMAN PHOSPODIESTERASE 4B IN COMPLEX WITH PYRIDYLOXY-BENZOXABOROLE BASED INHIBITOR
558, 3g4kC, 0.9065, 2.02, 0.245, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROLIPRAM
559, 1q9mC, 0.9065, 2.04, 0.245, 329, 306, THREE DIMENSIONAL STRUCTURES OF PDE4D IN COMPLEX WITH ROLIPRAMS AND IMPLICATION ON INHIBITOR SELECTIVITY
560, 3sl8A, 0.9062, 2.00, 0.246, 327, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10O
561, 3sl6A, 0.9062, 2.01, 0.246, 327, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 12C
562, 1xotA, 0.9062, 2.00, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH VARDENAFIL
563, 4ogbA, 0.9061, 2.00, 0.246, 328, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 2
564, 2fm5C, 0.9061, 2.04, 0.245, 327, 306, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR L- 869299
565, 2fm5B, 0.9061, 2.16, 0.244, 327, 307, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR L- 869299
566, 3wd9B, 0.9060, 2.40, 0.241, 345, 311, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 4B IN COMPLEX WITH COMPOUND 10F
567, 3sl6D, 0.9060, 1.98, 0.246, 324, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 12C
568, 4wcuD, 0.9059, 1.95, 0.250, 330, 304, PDE4 COMPLEXED WITH INHIBITOR
569, 3wd9A, 0.9059, 2.29, 0.243, 345, 309, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 4B IN COMPLEX WITH COMPOUND 10F
570, 3g58C, 0.9059, 2.05, 0.242, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155988/PMNPQ
571, 2h44A, 0.9059, 1.83, 0.395, 326, 301, CRYSTAL STRUCTURE OF PDE5A1 IN COMPLEX WITH ICARISID II
572, 1y2jA, 0.9059, 2.01, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH 35- DIMETHYL-1-(3-NITRO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
573, 4w1oA, 0.9057, 1.95, 0.250, 322, 304, PDE4D COMPLEXED WITH INHIBITOR
574, 1sojC, 0.9057, 1.84, 0.221, 364, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
575, 1sojK, 0.9056, 1.84, 0.221, 364, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
576, 1sojI, 0.9056, 1.84, 0.221, 364, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
577, 1sojA, 0.9056, 1.84, 0.221, 364, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
578, 4w1oC, 0.9055, 1.99, 0.246, 321, 305, PDE4D COMPLEXED WITH INHIBITOR
579, 1xlxA, 0.9054, 2.03, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH CILOMILAST
580, 1sojG, 0.9054, 1.84, 0.215, 364, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
581, 1sojE, 0.9054, 1.84, 0.215, 364, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
582, 1so2B, 0.9053, 1.94, 0.224, 363, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR
583, 5k32B, 0.9052, 1.90, 0.241, 321, 303, PDE4D CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
584, 4wziB, 0.9052, 2.29, 0.249, 424, 309, CRYSTAL STRUCTURE OF CROSSLINK STABILIZED LONG-FORM PDE4B
585, 1y2jB, 0.9052, 2.02, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH 35- DIMETHYL-1-(3-NITRO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
586, 3w5eA, 0.9051, 2.30, 0.243, 345, 309, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 4B IN COMPLEX WITH COMPOUND 31E
587, 4wcuA, 0.9050, 1.96, 0.250, 330, 304, PDE4 COMPLEXED WITH INHIBITOR
588, 4ogbB, 0.9050, 1.85, 0.254, 321, 303, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 2
589, 3v93B, 0.9050, 2.08, 0.198, 333, 308, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
590, 3ly2D, 0.9050, 2.18, 0.244, 328, 307, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
591, 3sl4C, 0.9049, 1.95, 0.247, 325, 304, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10D
592, 1y2hA, 0.9049, 2.03, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH 1-(2- CHLORO-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
593, 5u7dB, 0.9048, 1.95, 0.349, 328, 304, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
594, 1so2A, 0.9048, 2.10, 0.220, 363, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR
595, 3iadC, 0.9047, 1.94, 0.247, 339, 304, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH BOUND ALLOSTERIC MODULATOR
596, 5tkbB, 0.9046, 2.06, 0.246, 323, 305, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH A TETRAFLUORANLINE COMPOUND
597, 3k4sA, 0.9045, 2.11, 0.252, 329, 305, THE STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PDE4D WITH 4- (3-BUTOXY-4-METHOXYPHENYL)METHYL-2-IMIDAZOLIDONE
598, 1xlxB, 0.9045, 2.03, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH CILOMILAST
599, 5vydB, 0.9044, 1.77, 0.262, 317, 301, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE DOMAIN OF RHOPDE FUSION PROTEIN FROM THE CHOANOFLAGELLATE SALPINGOECA ROSETTA
600, 5k32A, 0.9044, 1.91, 0.241, 322, 303, PDE4D CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
601, 1y2hB, 0.9043, 2.03, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH 1-(2- CHLORO-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
602, 3sl6C, 0.9042, 1.97, 0.247, 325, 304, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 12C
603, 3v94E, 0.9041, 1.98, 0.199, 331, 306, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
604, 1so2D, 0.9041, 1.86, 0.221, 365, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR
605, 4wcuB, 0.9039, 2.05, 0.246, 333, 305, PDE4 COMPLEXED WITH INHIBITOR
606, 4ogbC, 0.9039, 1.96, 0.247, 325, 304, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 2
607, 3sl3B, 0.9039, 1.80, 0.255, 320, 302, CRYSTAL STRUCTURE OF THE APO FORM OF THE CATALYTIC DOMAIN OF PDE4D2
608, 5b25A, 0.9036, 1.83, 0.238, 335, 303, CRYSTAL STRUCTURE OF HUMAN PDE1B WITH INHIBITOR 3
609, 3sl3A, 0.9035, 2.13, 0.243, 327, 305, CRYSTAL STRUCTURE OF THE APO FORM OF THE CATALYTIC DOMAIN OF PDE4D2
610, 3v94D, 0.9032, 2.00, 0.199, 331, 306, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
611, 4wziA, 0.9031, 2.03, 0.249, 412, 305, CRYSTAL STRUCTURE OF CROSSLINK STABILIZED LONG-FORM PDE4B
612, 4w1oD, 0.9031, 1.92, 0.251, 317, 303, PDE4D COMPLEXED WITH INHIBITOR
613, 3v94C, 0.9031, 2.00, 0.199, 333, 306, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
614, 3ecmA, 0.9031, 2.12, 0.212, 338, 307, CRYSTAL STRUCTURE OF THE UNLIGANDED PDE8A CATALYTIC DOMAIN
615, 4wcuC, 0.9030, 1.93, 0.254, 322, 303, PDE4 COMPLEXED WITH INHIBITOR
616, 3v93E, 0.9030, 1.89, 0.201, 329, 304, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
617, 3sl5C, 0.9030, 1.98, 0.247, 325, 304, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 COMPLEXED WITH COMPOUND 10D
618, 3sl3C, 0.9030, 1.97, 0.247, 324, 304, CRYSTAL STRUCTURE OF THE APO FORM OF THE CATALYTIC DOMAIN OF PDE4D2
619, 3ecnB, 0.9029, 2.11, 0.212, 338, 307, CRYSTAL STRUCTURE OF PDE8A CATALYTIC DOMAIN IN COMPLEX WITH IBMX
620, 1xmyA, 0.9029, 2.01, 0.247, 321, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (R)- ROLIPRAM
621, 3v94G, 0.9028, 2.01, 0.199, 334, 306, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
622, 3iadA, 0.9027, 2.02, 0.243, 340, 304, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH BOUND ALLOSTERIC MODULATOR
623, 3ecnA, 0.9027, 2.13, 0.212, 338, 307, CRYSTAL STRUCTURE OF PDE8A CATALYTIC DOMAIN IN COMPLEX WITH IBMX
624, 6ezfA, 0.9026, 2.07, 0.352, 342, 304, PDE2 IN COMPLEX WITH MOLECULE 5
625, 3v94A, 0.9026, 2.01, 0.199, 332, 306, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
626, 1xm4B, 0.9026, 2.02, 0.247, 321, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH PICLAMILAST
627, 1xm4A, 0.9025, 2.02, 0.247, 321, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH PICLAMILAST
628, 3v94F, 0.9024, 2.01, 0.199, 334, 306, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
629, 5b25B, 0.9021, 1.86, 0.238, 332, 303, CRYSTAL STRUCTURE OF HUMAN PDE1B WITH INHIBITOR 3
630, 1xmuB, 0.9021, 2.02, 0.247, 321, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH ROFLUMILAST
631, 1xlzA, 0.9018, 2.03, 0.247, 321, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH FILAMINAST
632, 1xlzB, 0.9016, 2.04, 0.247, 321, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH FILAMINAST
633, 4x0fB, 0.9015, 2.07, 0.249, 414, 305, CRYSTAL STRUCTURE OF CROSSLINK STABILIZED LONG-FORM PDE4B IN COMPLEX WITH (R)-(-)-ROLIPRAM
634, 3iakA, 0.9015, 1.94, 0.252, 325, 302, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D (PDE4D) WITH PAPAVERINE.
635, 3v94B, 0.9014, 2.03, 0.199, 334, 306, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
636, 1xmyB, 0.9014, 2.04, 0.247, 321, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (R)- ROLIPRAM
637, 5b25D, 0.9009, 1.88, 0.238, 332, 303, CRYSTAL STRUCTURE OF HUMAN PDE1B WITH INHIBITOR 3
638, 3v93A, 0.9008, 1.93, 0.201, 329, 304, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
639, 3sl8C, 0.9007, 1.97, 0.244, 324, 303, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10O
640, 5b25C, 0.9004, 1.87, 0.238, 332, 303, CRYSTAL STRUCTURE OF HUMAN PDE1B WITH INHIBITOR 3
641, 1xosA, 0.8999, 2.01, 0.248, 319, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH SILDENAFIL
642, 3v93H, 0.8997, 1.89, 0.201, 328, 303, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
643, 3v94H, 0.8996, 2.00, 0.200, 330, 305, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
644, 1xn0A, 0.8993, 2.03, 0.248, 320, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (RS)- ROLIPRAM
645, 5xkmF, 0.8991, 1.88, 0.346, 321, 301, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
646, 1xn0B, 0.8987, 2.03, 0.248, 320, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (RS)- ROLIPRAM
647, 1xm6B, 0.8980, 2.06, 0.248, 331, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (R)- MESOPRAM
648, 1xm6A, 0.8976, 2.05, 0.248, 335, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (R)- MESOPRAM
649, 5uoyA, 0.8975, 1.86, 0.243, 321, 301, CRYSTAL STRUCTURE OF HUMAN PDE1B CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 16J (6-(4-METHOXYBENZYL)-9-((TETRAHYDRO-2H-PYRAN-4-YL) METHYL)-891011-TETRAHYDROPYRIDO[4 3 :45]THIENO[32-E][12 4]TRIAZOLO[15-C]PYRIMIDIN-5(6H)-ONE)
650, 5w6eA, 0.8974, 1.89, 0.242, 321, 302, PDE1B COMPLEXED WITH COMPOUND 3S 
651, 5up0A, 0.8974, 1.85, 0.243, 321, 301, CRYSTAL STRUCTURE OF HUMAN PDE1B CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 3 (6-(4-CHLOROBENZYL)-891011-TETRAHYDROBENZO[4 5]THIENO[32-E][124]TRIAZOLO[15-C]PYRIMIDIN-5(6H)-ONE)
652, 4npwA, 0.8974, 1.89, 0.242, 321, 302, CRYSTAL STRUCTURE OF HUMAN PDE1B BOUND TO INHIBITOR 19A (78- DIMETHOXY-N-[(2S)-1-(3-METHYL-1H-PYRAZOL-5-YL)PROPAN-2-YL]QUINAZOLIN- 4-AMINE)
653, 4npvA, 0.8971, 1.83, 0.243, 323, 301, CRYSTAL STRUCTURE OF HUMAN PDE1B BOUND TO INHIBITOR 7A (678- TRIMETHOXY-N-(PENTAN-3-YL)QUINAZOLIN-4-AMINE)
654, 4llpB, 0.8967, 1.36, 1.000, 304, 292, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT401
655, 3kktA, 0.8950, 2.19, 0.236, 347, 305, CRYSTAL STRUCTURE OF HUMAN PDE4B WITH 5-[3-[(1S2S4R)- BICYCLO[2.2.1]HEPT-2-YLOXY]-4-METHOXYP HENYL]TETRAHYDRO-2(1H)- PYRIMIDINONE REVEALS ORDERING OF THE C-TERMINAL HELIX RESIDUES 502- 509.
656, 4y2bA, 0.8929, 1.98, 0.257, 318, 303, CO-CRYSTAL STRUCTURE OF 3-ETHYL-2-(ISOPROPYLAMINO)-7-(PYRIDIN-3-YL) THIENO[32-D]PYRIMIDIN-4(3H)-ONE BOUND TO PDE7A
657, 3kktB, 0.8927, 2.33, 0.239, 338, 305, CRYSTAL STRUCTURE OF HUMAN PDE4B WITH 5-[3-[(1S2S4R)- BICYCLO[2.2.1]HEPT-2-YLOXY]-4-METHOXYP HENYL]TETRAHYDRO-2(1H)- PYRIMIDINONE REVEALS ORDERING OF THE C-TERMINAL HELIX RESIDUES 502- 509.
658, 5xkmE, 0.8925, 1.89, 0.348, 319, 299, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
659, 3g3nA, 0.8921, 1.99, 0.261, 318, 303, PDE7A CATALYTIC DOMAIN IN COMPLEX WITH 3-(26- DIFLUOROPHENYL)-2-(METHYLTHIO)QUINAZOLIN-4(3H)-ONE
660, 3v93D, 0.8903, 1.94, 0.203, 324, 300, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
661, 3jbqB, 0.8900, 2.52, 0.417, 328, 314, DOMAIN ORGANIZATION AND CONFORMATIONAL PLASTICITY OF THE G PROTEIN EFFECTOR PDE6
662, 3jbqF, 0.8896, 2.52, 0.417, 328, 314, DOMAIN ORGANIZATION AND CONFORMATIONAL PLASTICITY OF THE G PROTEIN EFFECTOR PDE6
663, 4pm0A, 0.8893, 2.12, 0.247, 318, 304, PDE7A CATALYTIC DOMAIN IN COMPLEX WITH 2-(CYCLOPENTYLAMINO)THIENO[32- D]PYRIMIDIN-4(3H)-ONE DERIVATIVE
664, 1zklA, 0.8892, 2.11, 0.247, 317, 304, MULTIPLE DETERMINANTS FOR INHIBITOR SELECTIVITY OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASES
665, 5c29B, 0.8890, 1.24, 0.997, 288, 288, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-5-METHYL-N-PROPYL- PYRIMIDIN-4-AMINE
666, 3bjcA, 0.8840, 2.21, 0.378, 311, 299, CRYSTAL STRUCTURE OF THE PDE5A CATALYTIC DOMAIN IN COMPLEX WITH A NOVEL INHIBITOR
667, 1rkpA, 0.8828, 2.18, 0.378, 311, 299, CRYSTAL STRUCTURE OF PDE5A1-IBMX
668, 5vp1C, 0.8823, 1.81, 0.354, 313, 294, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
669, 1tazA, 0.8818, 1.89, 0.236, 321, 297, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 1B
670, 3sieB, 0.8797, 1.74, 0.375, 300, 291, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
671, 2h40A, 0.8778, 2.25, 0.380, 311, 297, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF UNLIGANDED PDE5
672, 4dffB, 0.8764, 0.37, 1.000, 277, 277, THE SAR DEVELOPMENT OF DIHYDROIMIDAZOISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA
673, 5vp0C, 0.8760, 1.82, 0.356, 311, 292, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
674, 3sieA, 0.8741, 1.79, 0.376, 297, 290, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
675, 5u7lB, 0.8707, 1.78, 0.352, 310, 290, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
676, 3shyA, 0.8694, 1.81, 0.381, 298, 289, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
677, 4md6A, 0.8665, 1.89, 0.381, 299, 289, CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH INHIBITOR 5R
678, 3shzA, 0.8661, 1.85, 0.378, 297, 288, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
679, 4i9zA, 0.8634, 1.74, 0.385, 296, 286, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
680, 3ibjB, 0.8601, 2.19, 0.326, 643, 291, X-RAY STRUCTURE OF PDE2A
681, 4oexA, 0.8596, 1.86, 0.381, 297, 286, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
682, 4g2yA, 0.8589, 1.91, 0.399, 297, 286, CRYSTAL STRUCTURE OF PDE5A COMPLEXED WITH ITS INHIBITOR
683, 3ibjA, 0.8531, 2.13, 0.333, 661, 288, X-RAY STRUCTURE OF PDE2A
684, 4ia0A, 0.8519, 1.75, 0.387, 292, 282, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
685, 4oewA, 0.8469, 1.82, 0.388, 289, 281, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
686, 3b2rA, 0.8461, 1.92, 0.379, 297, 282, CRYSTAL STRUCTURE OF PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH VARDENAFIL
687, 3itmB, 0.8426, 2.31, 0.324, 318, 287, CATALYTIC DOMAIN OF HPDE2A
688, 3itmD, 0.8425, 2.29, 0.328, 318, 287, CATALYTIC DOMAIN OF HPDE2A
689, 4g2wA, 0.8420, 1.65, 0.388, 286, 278, CRYSTAL STRUCTURE OF PDE5A IN COMPLEX WITH ITS INHIBITOR
690, 3b2rB, 0.8362, 1.98, 0.376, 287, 279, CRYSTAL STRUCTURE OF PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH VARDENAFIL
691, 3itmA, 0.8336, 2.41, 0.323, 307, 285, CATALYTIC DOMAIN OF HPDE2A
692, 3itmC, 0.8328, 2.36, 0.324, 310, 284, CATALYTIC DOMAIN OF HPDE2A
693, 1t9rA, 0.8313, 2.47, 0.363, 301, 284, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A
694, 2qymA, 0.7812, 2.44, 0.252, 291, 270, CRYSTAL STRUCTURE OF UNLIGANDED PDE4C2
